A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.

Also called NCT03170518

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 171 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03170518
  • EudraCT 2016-005223-88
Other papers using this trial's data
  • Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial Annals of internal medicine, 2025-09 DOI, PubMed 40759025

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, China, Greece, India, Malaysia, Mexico, Philippines, Poland, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03170518. Randomized; double masking; primary purpose treatment. Start 2017-07-21 (actual); primary completion 2023-09-20 (actual). Results posted on 2025-03-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canagliflozin 100 mg
Intervention (Drug)
Canagliflozin 300 mg
Intervention (Drug)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct03170518
Content hash
3770c3c4018cddf431cef200c542bf9c7f8b460ed5deddbf8abebcb66d9b59ed